LUND, SWEDEN, June 26, 2020 /PRNewswire/
-- Immunovia AB (publ) ("Immunovia") today
announced the registration details for the company's Virtual
Investor Day on Tuesday, June 30,
2020, from 2:00 to 4:00 pm
CET.
The online event will feature presentations by Immunovia's
Chairman, Carl Borrebaeck; CEO,
Mats Grahn; Chief Commercial
Officer, Laura Chirica; Senior VP
Sales North America, Michael
Pettigrew; and Dr Thomas
King, Medical Director.
Please register for Immunovia's Virtual Investor Day on
June 30, 2020 2:00 PM CET at:
https://attendee.gotowebinar.com/register/9213689045753501711
After registering, you will receive a confirmation email
containing information about joining the webinar.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber,
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/registration-details-for-immunovia-s-virtual-investor-day-on-tuesday--june-30--2020,c3142960
The following files are available for download:
https://mb.cision.com/Main/13121/3142960/1270496.pdf
|
Release
|